Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 12Brain Neoplasms 7Medulloblastoma 4Central Nervous System Neoplasms 4Astrocytoma 4Glioma 3Recurrence 2Neoplasms 2Spinal Cord Neoplasms 1Lymphoma, AIDS-Related 1Gliosarcoma 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Recurrence × Lomustine × Clear all
NCT02986178 2025-07-11

Lerapolturev in Recurrent Malignant Glioma

Istari Oncology, Inc.

Phase 2 Completed
121 enrolled 15 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma, Recurrence

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡